ReviewInflammopharmacology2026
Bioactive compounds of Glycyrrhiza glabra and their functional role in modulating gut inflammation and intestinal homeostasis.
Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review critically examines the therapeutic potential of Glycyrrhiza glabra (licorice) and its bioactive compounds in supporting gastrointestinal health. The botanical profile, historical medicinal applications, and principal bioactive compounds, including glycyrrhizin, flavonoids, and polysaccharides, are described. Mechanistic insights reveal that G. glabra exerts multifaceted actions, including anti-inflammatory, antioxidant, immunomodulatory, barrier-enhancing, and microbiota-regulating effects, which contribute to the maintenance of intestinal homeostasis. An extensive evaluation of experimental and clinical studies demonstrates protective roles for G. glabra in disorders such as inflammatory bowel disease, gastritis, peptic ulcer disease, and irritable bowel syndrome. While clinical investigations and meta-analyses validate its symptom-alleviating properties and favorable safety profile at recommended dosages, potential adverse effects and contraindications warrant consideration. This review concludes by outlining current research gaps and highlighting future directions, emphasizing the need for rigorous clinical trials and mechanistic studies. Collectively, current evidence supports G. glabra as a promising phytopharmacological candidate for further investigation in the integrative management of gut inflammation, although additional clinical validation is required.
Indexed as
Identifiers
42371378What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.